MARKET

NOVN

NOVN

Novan Inc
NASDAQ
1.180
+0.020
+1.72%
After Hours: 1.130 -0.05 -4.24% 16:29 12/05 EST
OPEN
1.240
PREV CLOSE
1.160
HIGH
1.260
LOW
1.080
VOLUME
494.21K
TURNOVER
0
52 WEEK HIGH
5.08
52 WEEK LOW
0.7900
MARKET CAP
28.87M
P/E (TTM)
-0.6109
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 4d ago
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasda...
GlobeNewswire · 4d ago
Novan stock tumbles 18% on Q3 revenue miss as key skin drugs sales fall Q/Q
Seekingalpha · 11/14 16:56
Novan Q3 EPS $(0.43) Misses $(0.39) Estimate, Sales $5.12M Miss $6.21M Estimate
Benzinga · 11/14 12:16
Novan GAAP EPS of -$0.25 beats by $0.14, revenue of $5.11M misses by $1.17M
Seekingalpha · 11/14 12:07
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 – – Company to host conference call t...
GlobeNewswire · 11/14 12:00
-- Earnings Flash (NOVN) NOVAN Posts Q3 Revenue $5.1M, vs. Street Est of $6.3M
-- Earnings Flash (NOVN) NOVAN Posts Q3 Revenue $5.1M, vs. Street Est of $6.3M
MT Newswires · 11/14 07:12
More
About NOVN
Novan, Inc.is a pre-commercial nitric oxide-based pharmaceutical company. The Company is engaged in researching, developing and marketing products for skin diseases. The Company is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The Company has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The Company is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

Webull offers kinds of Novan Inc stock information, including NASDAQ:NOVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NOVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NOVN stock methods without spending real money on the virtual paper trading platform.